𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

✍ Scribed by Klaus Fabel; Jörg Dietrich; Peter Hau; Caecilie Wismeth; Beate Winner; Saskia Przywara; Andreas Steinbrecher; Winfried Ullrich; Ulrich Bogdahn

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
88 KB
Volume
92
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pegylated liposomal doxorubicin-efficacy
Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma
✍ Peter Hau; Klaus Fabel; Ulrike Baumgart; Petra Rümmele; Oliver Grauer; Annekatri 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

## Abstract ## BACKGROUND Doxorubicin exhibits high efficacy in malignant glioma cell cultures. Nonetheless, as a standard formulation, doxorubicin has not been used clinically, due to poor penetration of the blood‐brain barrier. Furthermore, doxorubicin is known to induce tumor resistance genes.

Phase I study of pegylated liposomal dox
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies
✍ Paula M. Fracasso; Kristie A. Blum; Benjamin R. Tan; Carole L. Fears; Nancy L. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and gemcitabine have single‐agent activity in breast and ovarian carcinoma patients. We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancie

Phase I dose and sequencing study of peg
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
✍ Paula M. Fracasso; Luis C. Rodriguez; Thomas J. Herzog; Carole L. Fears; Sherry 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 1 views

## Abstract ## BACKGROUND Pegylated liposomal doxorubicin (PEG‐LD) and docetaxel have single‐agent activity in several malignancies. The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with ad

Prognostic factors for long term results
Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors
✍ Vincent L. M. Vander Poorten; Alfonsus J. M. Balm; Frans J. M. Hilgers; I. Bing 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## BACKGROUND. Concerning malignant submandibular gland tumors, a rare disease entity, there are few recent reports of long term treatment results and of prognostic factors modifying these results. ## METHODS. The clinical data of 43 patients with malignant submandibular gland tumors who were t